glp-1 therapy for Patients with Obesity GLP-1-based therapies for diabetes, obesity

The area under the tongue has a rich supply of blood vessels, which allows the medication to bypass the digestive system and liver

Obese patients with higher BMIs are at higher risk for having vitamin B12 deficiency and weight loss may potentially worsen the B12 deficiency

It is approved for individuals with a body mass index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who also have at least one weight-related condition such as high blood pressure, high cholesterol, or sleep apnea

Key Players In The Global Weight Loss Drugs Market Major companies operating in the weight loss drugs market are Pfizer Inc

While GLP-1s had mostly been prescribed for patients with type 2 diabetes as recently as two years ago (as of May 2024), the number of patients without a diabetes diagnosis using GLP-1s for weight loss has risen exponentially for example, they grew from 21K in 2019 to 174K in 2023, an increase of more than 700%

But about 2 in 5 adults used GLP-1 drugs solely to lose weight, the KFF poll found